查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1451625

2024-2032 年按产品、类型、疾病、应用、最终用户和地区分類的生物标记市场报告

Biomarkers Market Report by Product, Type, Disease, Application, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

2023年全球生物标记市场规模达到799亿美元。展望未来， IMARC Group预计到2032年市场规模将达到2,207亿美元，2024-2032年复合年增长率（CAGR）为11.37%。慢性病盛行率的上升、生物技术和基因组学的不断发展、向个性化医疗的转变、分析技术的不断进步以及医疗保健专业人员和患者对生物标誌物益处的认识不断提高是推动市场的一些主要因素。

生物标记是人体内可测量的指标，提供各种生物过程和条件的基本资讯。这些标记可以涵盖多种物质，包括蛋白质、基因、激素，甚至物理特征。生物标记在医学研究、诊断和治疗计划中发挥着至关重要的作用。它们使医疗保健专业人员和研究人员能够评估疾病的存在或进展、监测治疗的有效性并预测个人对某些健康问题的易感性。在市场研究和咨询服务领域，了解生物标记至关重要，因为它们指导医疗保健和製药行业的决策过程，有助于开发创新解决方案和策略。

癌症、心血管疾病和糖尿病等慢性疾病的增加是推动全球市场成长的关键因素之一。它们对于早期检测、疾病监测和个人化治疗策略的发展是不可或缺的。生物技术和基因组学的不断进步导致了新型生物标记的发现，扩大了其在诊断、药物开发和精准医学领域的应用。生物标记是药物研究不可或缺的一部分，有助于目标识别、候选药物功效评估和安全性分析。这加速了药物开发、降低了成本并提高了成功率。向个人化医疗的转变在很大程度上依赖生物标记来根据个别患者的情况量身定制治疗计划，改善治疗结果并最大限度地减少副作用。全球人口老化是关键驱动因素，因为老年人更容易患慢性病，因此需要利用生物标记进行早期检测和有效管理。基因组学、蛋白质组学和成像等分析技术的不断改进提高了生物标记检测的灵敏度和特异性，从而扩大了其应用范围，从而促进了全球市场的成长。

生物标记物市场趋势/驱动因素：

疾病负担和医疗费用不断上升

生物标记市场的主要驱动力之一是全球疾病负担不断升级，特别是癌症、心血管疾病和糖尿病等慢性病。生物标记在这些疾病的早期检测、诊断和监测中发挥关键作用。它们使医疗保健专业人员能够更有效地识别疾病风险、制定治疗策略并追踪治疗反应。由于医疗保健系统面临着管理这些日益增加的疾病负担的挑战，生物标记提供了一个有价值的工具，可以透过早期干预和标靶治疗来改善患者的治疗结果并降低医疗保健成本。

生物技术和个人化医疗的重大进步

生物技术工具和技术（包括基因组学、蛋白质组学和高通量筛选）的不断进步，彻底改变了生物标记的发现和验证。这导致了具有高特异性和敏感性的新型生物标记的鑑定，增强了其诊断和预后能力。此外，向个人化医疗的范式转变在很大程度上依赖生物标记来根据个别患者的情况量身定制治疗方案。生物标记驱动的方法使医疗保健提供者能够选择最合适的疗法，从而提高治疗效果并最大限度地减少不良反应。这不仅改善了患者护理，而且还增加了对基于生物标记的测试和治疗的需求。

药物开发和临床试验的增加

生物标记在製药业中变得不可或缺，推动药物发现和开发，从而成为主要的成长诱导因素。它们有助于目标识别、临床试验的患者分层以及药物疗效和安全性的评估。这可以简化药物开发流程、降低成本并提高将新药推向市场的成功率。 FDA 和 EMA 等监管机构越来越认识到生物标记在药物审批中的重要性，这进一步加速了生物标记融入临床试验和药物开发管道。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球生物标记市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依产品

  • 耗材
    • 市场走向
    • 市场预测
  • 服务
    • 市场走向
    • 市场预测
  • 软体
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按类型

  • 功效生物标记
    • 市场走向
    • 市场预测
  • 安全生物标记
    • 市场走向
    • 市场预测
  • 验证生物标记
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依疾病分类

  • 癌症
    • 市场走向
    • 市场预测
  • 心血管疾病
    • 市场走向
    • 市场预测
  • 神经系统疾病
    • 市场走向
    • 市场预测
  • 免疫系统疾病
    • 市场走向
    • 市场预测
  • 肾臟疾病
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按应用

  • 诊断
    • 市场走向
    • 市场预测
  • 药物发现与开发
    • 市场走向
    • 市场预测
  • 个人化医疗
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 10 章：市场区隔：依最终用户

  • 製药和生物技术公司
    • 市场走向
    • 市场预测
  • 诊断与研究实验室
    • 市场走向
    • 市场预测
  • 医院和专科诊所
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 11 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 12 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 13 章：价值链分析

第 14 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 15 章：价格分析

第16章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Agilent Technologies Inc.
    • Bio-Rad Laboratories Inc.
    • Charles River Laboratories International Inc.
    • Epigenomics AG
    • Eurofins Scientific SE
    • Merck KGaA
    • Perkinelmer Inc.
    • Qiagen NV
    • Quanterix Corporation
    • SphingoTec GmbH
    • Thermo Fisher Scientific Inc.
Product Code: SR112024A6320

The global biomarkers market size reached US$ 79.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 220.7 Billion by 2032, exhibiting a growth rate (CAGR) of 11.37% during 2024-2032. The rising prevalence of chronic diseases, ongoing developments in biotechnology and genomics, the shift toward personalized medicine, continuous advancements in analytical technologies, and increasing awareness among both healthcare professionals and patients about the benefits of biomarkers are some of the major factors propelling the market.

Biomarkers are measurable indicators within the human body that provide essential information about various biological processes and conditions. These markers can encompass a wide range of substances, including proteins, genes, hormones, or even physical characteristics. Biomarkers play a crucial role in medical research, diagnosis, and treatment planning. They enable healthcare professionals and researchers to assess the presence or progression of diseases, monitor the effectiveness of therapies, and predict an individual's susceptibility to certain health issues. In the realm of market research and consulting services, understanding biomarkers is pivotal, as they guide decision-making processes in healthcare and pharmaceutical industries, aiding in the development of innovative solutions and strategies.

The rise in chronic diseases, including cancer, cardiovascular disorders, and diabetes, represents one of the key factors driving the growth of the market across the globe. They are indispensable for early detection, disease monitoring, and the development of personalized treatment strategies. The continuous progress in biotechnology and genomics is leading to the discovery of novel biomarkers, expanding their applications across diagnostics, drug development, and precision medicine. Biomarkers are integral to pharmaceutical research, assisting in target identification, drug candidate efficacy evaluation, and safety profiling. This accelerates drug development, reduces costs, and enhances success rates. The shift towards personalized medicine relies heavily on biomarkers to tailor treatment plans to individual patient profiles, improving treatment outcomes and minimizing side effects. The globally aging population is a key driver, as elderly individuals are more prone to chronic diseases, necessitating early detection and effective management using biomarkers. Continuous improvements in analytical technologies, such as genomics, proteomics, and imaging enhance the sensitivity and specificity of biomarker detection, which is broadening their applications, thus facilitating the market growth across the globe.

Biomarkers Market Trends/Drivers:

Rising disease burden and healthcare costs

One of the primary drivers of the biomarkers market is the escalating global burden of diseases, particularly chronic conditions like cancer, cardiovascular diseases, and diabetes. Biomarkers play a pivotal role in the early detection, diagnosis, and monitoring of these diseases. They enable healthcare professionals to identify disease risks, formulate treatment strategies, and track treatment responses more effectively. As healthcare systems face the challenge of managing these increasing disease burdens, biomarkers provide a valuable tool for improving patient outcomes and reducing healthcare costs through early intervention and targeted therapies.

Significant advancements in biotechnology and personalized medicine

The continuous advancement of biotechnological tools and techniques, including genomics, proteomics, and high-throughput screening, has revolutionized biomarker discovery and validation. This has led to the identification of novel biomarkers with high specificity and sensitivity, enhancing their diagnostic and prognostic capabilities. Moreover, the paradigm shift towards personalized medicine relies heavily on biomarkers to tailor treatments to individual patient profiles. Biomarker-driven approaches enable healthcare providers to select the most suitable therapies, thereby increasing treatment efficacy and minimizing adverse effects. This has not only improved patient care but has also intensified the demand for biomarker-based tests and therapies.

Rise in drug development and clinical trials

Biomarkers are becoming indispensable in the pharmaceutical industry, which is driving drug discovery and development, thus acting as a major growth-inducing factor. They facilitate target identification, patient stratification for clinical trials, and assessment of drug efficacy and safety. This results in streamlined drug development processes, reduced costs, and increased success rates in bringing new drugs to market. Regulatory agencies, such as the FDA and EMA, increasingly recognize the significance of biomarkers in drug approvals, which is further accelerating their integration into clinical trials and drug development pipelines.

Biomarkers Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global biomarkers market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, type, disease, application, and end user.

Breakup by Product:

Consumables

Services

Software

Consumables dominate the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes consumables, services, and software. According to the report, consumables represented the largest segment.

The demand for consumables in the biomarkers market is driven by several influential factors. Primarily, the continuous expansion of biomarker research in various fields, including oncology, cardiology, and neuroscience, necessitates a steady supply of consumables. Researchers rely on consumables such as assay kits, reagents, and laboratory supplies to conduct experiments and validate biomarkers for clinical applications. The growing adoption of biomarkers for clinical diagnostics fuels demand for consumables used in diagnostic tests. Consumables like test kits, sample collection devices, and assay reagents are essential for accurate biomarker-based diagnosis, enabling early disease detection and monitoring. Biomarkers are integral to drug discovery and development, where consumables like cell culture media, plates, and assay components are essential. The pharmaceutical industry's robust pipeline of biomarker-driven therapies and the need for large-scale screening drive demand for consumables. The trend towards personalized medicine, which relies on biomarkers for treatment tailoring, has increased the need for consumables. Customized therapies based on individual biomarker profiles require specific consumables for their development and administration.

Breakup by Type:

Efficacy Biomarkers

Safety Biomarkers

Validation Biomarkers

Safety biomarkers hold the largest share in the market

The report has provided a detailed breakup and analysis of the market based on the type. This includes efficacy biomarkers, safety biomarkers, and validation biomarkers. According to the report, safety biomarkers represented the largest segment.

The demand for safety biomarkers in the biomarkers industry is influenced by several critical factors. Regulatory agencies, such as the FDA and EMA, mandate the evaluation of safety biomarkers in drug development to assess potential adverse effects and toxicity. Compliance with these regulations drives the demand for safety biomarker assays and testing services. The high costs associated with drug development, including the expenses incurred due to adverse events and late-stage failures, underscore the importance of safety biomarkers. Early detection of safety concerns can significantly reduce development expenses, prompting the pharmaceutical industry to invest in safety biomarker research and implementation. Ensuring patient safety is paramount in clinical trials. The utilization of safety biomarkers helps identify and mitigate potential risks to participants, aligning with ethical and safety considerations. Technological advancements, such as omics technologies (genomics, proteomics, metabolomics), enable the discovery of novel safety biomarkers with enhanced sensitivity and specificity. The availability of cutting-edge tools and assays drives the adoption of safety biomarkers in drug safety assessment.

Breakup by Disease:

Cancer

Cardiovascular Disorders

Neurological Disorders

Immunological Disorders

Renal Disorders

Others

Cancer dominates the market

The report has provided a detailed breakup and analysis of the market based on the disease. This includes cancer, cardiovascular disorders, neurological disorders, immunological disorders, renal disorders, and others. According to the report, cancer represented the largest segment.

Biomarkers play a pivotal role in cancer research, diagnosis, treatment, and patient management. Their applications in cancer are multifaceted and essential. Primarily, biomarkers enable the early detection of cancer, often before symptoms manifest. Blood-based biomarkers, such as circulating tumor DNA (ctDNA) and specific proteins like PSA (Prostate-Specific Antigen), aid in screening and early diagnosis. Biomarkers help confirm cancer diagnoses and classify tumors into specific subtypes. For instance, hormone receptor status (estrogen and progesterone receptors) in breast cancer guides treatment decisions. Biomarkers provide prognostic information, helping predict the course of the disease. Genetic markers and gene expression profiles assist in estimating a patient's likely outcome and risk of recurrence. Biomarkers guide treatment decisions by identifying targeted therapies. For instance, the presence of HER2/neu in breast cancer indicates eligibility for HER2-targeted therapies like trastuzumab. Biomarkers are used to monitor treatment efficacy and disease progression. Imaging biomarkers, like PET scans, assess tumor response to therapy, aiding treatment adjustments.

Breakup by Application:

Diagnostics

Drug Discovery and Development

Personalized Medicine

Others

Drug discovery and development hold the largest share in the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes diagnostics, drug discovery and development, personalized medicine, and others. According to the report, drug discovery and development represented the largest segment.

Biomarkers are indispensable tools in drug discovery and development, offering several critical applications that streamline the process and increase its efficiency. Biomarkers help identify and validate potential drug targets by providing insights into their role in disease pathways. This ensures that drug development efforts are focused on biologically relevant targets. Biomarkers aid in assessing the effectiveness of drug candidates during preclinical and clinical trials. They provide quantifiable measurements of the drug's impact on the target and its downstream effects, helping to select the most promising candidates. Safety biomarkers are crucial for evaluating the potential adverse effects of drug candidates. They help identify safety concerns early in the development process, reducing the risk of late-stage failures. Biomarkers enable the stratification of patient populations, identifying subgroups that are more likely to respond to a specific treatment. This supports the development of targeted therapies, optimizing treatment outcomes.

Breakup by End User:

Pharmaceutical and Biotechnology Companies

Diagnostic and Research Laboratories

Hospitals and Specialty Clinics

Others

Diagnostic and research laboratories dominates the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes pharmaceutical and biotechnology companies, diagnostic and research laboratories, hospitals and specialty clinics, and others. According to the report, diagnostic and research laboratories represented the largest segment.

Biomarkers have a significant impact on the operations of diagnostic and research laboratories, serving a wide range of crucial purposes. Biomarkers are fundamental in clinical diagnostics, aiding in the accurate and early diagnosis of various diseases. They provide measurable indicators of disease presence or progression, enhancing diagnostic precision. Biomarkers enable the categorization of patients into different risk groups or disease subtypes, helping healthcare providers tailor treatment plans to individual profiles. In research and clinical settings, biomarkers are used to monitor disease progression and assess the effectiveness of treatments. This helps in disease management and optimization of therapeutic interventions. Laboratories use biomarkers to evaluate drug responses, assess drug metabolism, and understand the relationship between drug dose and effect. Biomarkers play a role in assessing the safety of drugs and therapies and identifying potential side effects and toxicities. Biomarkers serve as key tools in laboratory research, aiding in the discovery of new disease mechanisms, drug targets, and potential therapeutic interventions.

Breakup by Region:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Russia

Spain

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Russia, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The biomarkers industry in North America is driven by several influential factors that contribute to its growth and development. The high prevalence of chronic diseases, including cancer, cardiovascular disorders, and diabetes, in North America has fueled the demand for biomarkers. Biomarkers are crucial for early detection, monitoring, and treatment selection in these conditions. North America boasts a well-developed healthcare infrastructure, including state-of-the-art laboratories and research facilities. This infrastructure supports biomarker research, development, and implementation. The region is home to a robust biotechnology and pharmaceutical industry. Biomarkers play a central role in drug discovery, development, and clinical trials, driving their demand. Regulatory agencies like the FDA in the United States have recognized the importance of biomarkers in drug development and diagnostics. Clear regulatory pathways for biomarker-based products encourage their use. Significant investments in research and development (R&D), both public and private, support biomarker discovery and validation, enhancing their role in healthcare. Ongoing technological advancements in genomics, proteomics, and diagnostic technologies are improving the accuracy and efficiency of biomarker assays.

Competitive Landscape:

Key players in the market are actively engaged in various strategic initiatives to advance research, development, and commercialization in this dynamic field. Leading companies invest heavily in R&D to discover and validate novel biomarkers. They collaborate with academic institutions and research organizations to expand their biomarker portfolios. Many biomarker companies form strategic partnerships with pharmaceutical and biotechnology firms to integrate biomarkers into drug development pipelines. These collaborations aim to identify biomarkers for patient stratification and treatment response prediction. Companies continuously expand their biomarker product portfolios, offering a wide range of assays, kits, and services for diverse applications, from diagnostics to drug development. Leading players invest in cutting-edge technologies, such as next-generation sequencing and mass spectrometry, to enhance the sensitivity and specificity of biomarker detection methods. Some key players focus on developing companion diagnostics, and aligning biomarker tests with specific therapies to ensure precise treatment selection and improve patient outcomes.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Agilent Technologies Inc.

Bio-Rad Laboratories Inc.

Charles River Laboratories International Inc.

Epigenomics AG

Eurofins Scientific SE

Merck KGaA

Perkinelmer Inc.

Qiagen N.V

Quanterix Corporation

SphingoTec GmbH

Thermo Fisher Scientific Inc.

Recent Developments:

In June 2023, FDA announced a new voluntary pilot program for certain oncology drug products used with certain corresponding in-vitro diagnostic tests. The goal of this program is to help clinicians select appropriate cancer treatments for patients.

In March 2022, Union Health Minister Mansukh Madaviya launched the Diet and Biomarkers Survey in India (DABS-I) at the National Institute of Nutrition (NIN) here on Saturday.

November 30, 2020, Agilent announced launch of global biomarker pathologist training program, designed to enrich pathologists' skills in biomarker interpretation and scoring techniques.

Key Questions Answered in This Report

  • 1. What was the size of the global biomarkers market in 2023?
  • 2. What is the expected growth rate of the global biomarkers market during 2024-2032?
  • 3. What are the key factors driving the global biomarkers market?
  • 4. What has been the impact of COVID-19 on the global biomarkers market?
  • 5. What is the breakup of the global biomarkers market based on the product?
  • 6. What is the breakup of the global biomarkers market based on the type?
  • 7. What is the breakup of the global biomarkers market based on disease?
  • 8. What is the breakup of the global biomarkers market based on the application?
  • 9. What is the breakup of the global biomarkers market based on the end user?
  • 10. What are the key regions in the global biomarkers market?
  • 11. Who are the key players/companies in the global biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biomarkers Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Consumables
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Services
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Software
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Efficacy Biomarkers
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Safety Biomarkers
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Validation Biomarkers
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Disease

  • 8.1 Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cardiovascular Disorders
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Neurological Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Immunological Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Renal Disorders
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Diagnostics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Drug Discovery and Development
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Personalized Medicine
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Pharmaceutical and Biotechnology Companies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Diagnostic and Research Laboratories
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Hospitals and Specialty Clinics
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Agilent Technologies Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Bio-Rad Laboratories Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Charles River Laboratories International Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Epigenomics AG
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Eurofins Scientific SE
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Merck KGaA
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Perkinelmer Inc.
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Qiagen N.V
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Quanterix Corporation
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
    • 16.3.10 SphingoTec GmbH
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
    • 16.3.11 Thermo Fisher Scientific Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Biomarkers Market: Major Drivers and Challenges
  • Figure 2: Global: Biomarkers Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Biomarkers Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Biomarkers Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Biomarkers Market: Breakup by Type (in %), 2023
  • Figure 6: Global: Biomarkers Market: Breakup by Disease (in %), 2023
  • Figure 7: Global: Biomarkers Market: Breakup by Application (in %), 2023
  • Figure 8: Global: Biomarkers Market: Breakup by End User (in %), 2023
  • Figure 9: Global: Biomarkers Market: Breakup by Region (in %), 2023
  • Figure 10: Global: Biomarkers (Consumables) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Biomarkers (Consumables) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Biomarkers (Services) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Biomarkers (Services) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Biomarkers (Software) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Biomarkers (Software) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Biomarkers (Efficacy Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Biomarkers (Efficacy Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Biomarkers (Safety Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Biomarkers (Safety Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Biomarkers (Validation Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Biomarkers (Validation Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Biomarkers (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Biomarkers (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Biomarkers (Cardiovascular Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Biomarkers (Cardiovascular Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Biomarkers (Neurological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Biomarkers (Neurological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Biomarkers (Immunological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Biomarkers (Immunological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Biomarkers (Renal Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Biomarkers (Renal Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Biomarkers (Other Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Biomarkers (Other Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Biomarkers (Diagnostics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Biomarkers (Diagnostics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Biomarkers (Drug Discovery and Development) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Biomarkers (Drug Discovery and Development) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Biomarkers (Personalized Medicine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Biomarkers (Personalized Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Biomarkers (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: Biomarkers (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Global: Biomarkers (Pharmaceutical and Biotechnology Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Global: Biomarkers (Pharmaceutical and Biotechnology Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Global: Biomarkers (Diagnostic and Research Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Global: Biomarkers (Diagnostic and Research Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Global: Biomarkers (Hospitals and Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Global: Biomarkers (Hospitals and Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Global: Biomarkers (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Global: Biomarkers (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: North America: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: North America: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: United States: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: United States: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Canada: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Canada: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Asia-Pacific: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Asia-Pacific: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: China: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: China: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Japan: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Japan: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: India: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: India: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: South Korea: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: South Korea: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Australia: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Australia: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Indonesia: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Indonesia: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Europe: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Europe: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Germany: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Germany: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: France: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: France: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: United Kingdom: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: United Kingdom: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Italy: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Italy: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Spain: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Spain: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Russia: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Russia: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Others: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Others: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Latin America: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Latin America: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Brazil: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Brazil: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Mexico: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 93: Mexico: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 94: Others: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 95: Others: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 96: Middle East and Africa: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 97: Middle East and Africa: Biomarkers Market: Breakup by Country (in %), 2023
  • Figure 98: Middle East and Africa: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 99: Global: Biomarkers Industry: SWOT Analysis
  • Figure 100: Global: Biomarkers Industry: Value Chain Analysis
  • Figure 101: Global: Biomarkers Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Biomarkers Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Biomarkers Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Biomarkers Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 4: Global: Biomarkers Market Forecast: Breakup by Disease (in Million US$), 2024-2032
  • Table 5: Global: Biomarkers Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 6: Global: Biomarkers Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 7: Global: Biomarkers Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Biomarkers Market: Competitive Structure
  • Table 9: Global: Biomarkers Market: Key Players